Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 19A in children: a meta-analysis.
- Author:
Zhao Jun LU
1
;
Yan LIU
1
;
Jian DU
1
;
Jun WANG
1
;
Xin Ren CHE
1
;
Wei JIANG
1
;
Xiao Ping ZHANG
1
;
Wen Wen GU
1
;
Yu Yang XU
1
;
Xue Chao ZHANG
1
;
Jing WANG
1
;
Qi Xin XIE
1
;
Ying Ying YANG
1
;
Lin Tao GU
1
Author Information
- Publication Type:Journal Article
- MeSH: Child; Humans; Child, Preschool; Case-Control Studies; Cohort Studies; Serogroup; Vaccines, Conjugate/therapeutic use*; China; Pneumococcal Infections/prevention & control*
- From: Chinese Journal of Preventive Medicine 2023;57(12):2181-2187
- CountryChina
- Language:Chinese
- Abstract: Objective: Using Meta-analysis to evaluate the vaccine effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) against invasive Streptococcus pneumoniae disease (IPD) caused by serotype 19A in children <5 years old. Methods: "Streptococcus pneumoniae infection""invasive pneumococcal disease""13-valent pneumococcal polysaccharide conjugate vaccine""PCV13""effectiveness""infant""child" and related terms were searched from China National Knowledge Infrastructure (CNKI), WANFANG DATA, PubMed, SCOPUS and Web of science with no limited on language, region and research institution. The retrieval time was limited from January 2010 to February 2023 and cohort study, case-control study and randomized controlled trial were included. Data were extracted from eligible studies by two independent reviewers, and after study quality assessment by NOS scale, Meta-analysis was completed using Stata 16.0 software. Results: A total of 2 340 related literatures were searched, and 10 literatures were finally included, including 5 case-control studies and 5 indirect cohort studies, which showed good literature quality. The vaccine effectiveness against serotype 19A IPD of PCV13 in children was 83.91% (95%CI: 78.92%-88.89%), and the subgroup analysis (P=0.240) showed there was no significant difference among the case-control study (VE=87.34%, 95%CI:79.74%-94.94%) and the indirect cohort study (VE=81.30%, 95%CI:74.69%-87.92%). The funnel plot and Egger test suggested that the possibility of publication bias was small. Conclusion: The present evidence indicates that PCV13 has a good vaccine effectiveness against serotype 19A IPD in children, and it is recommended to further increase the vaccination rate of PCV13 to reduce the disease burden of IPD in children <5 years old.
